Asembia AXS26: Jessica Lovett on the RWE That Matters Most

Key Takeaways

• Patient support programs provide direct, real-time outcome data.
• Registries enable longitudinal tracking across treatment journeys.
• Canadian market offers unique data opportunities for specialty drugs.
• RWE informs development, regulatory, and post‑market strategies.
• Leveraging RWE improves patient access and payer confidence.

Pulse Analysis

The Asembia AXS26 conference has become a bellwether for how the pharmaceutical industry is integrating real‑world evidence into every phase of a specialty therapy’s lifecycle. Jessica Lovett’s remarks reflect a broader shift: decision‑makers now demand data that go beyond controlled trial endpoints to capture the nuances of everyday clinical practice. By positioning RWE as a strategic asset, firms can accelerate development timelines, strengthen regulatory dossiers, and demonstrate value to health‑system payers who increasingly tie reimbursement to real‑world outcomes.

Patient support programs are emerging as a rich, under‑utilized source of real‑world data. These initiatives, which often include medication adherence tools, financial assistance, and disease‑specific education, generate granular patient‑level information on treatment response, side‑effect management, and access barriers. When analyzed across Canadian and global cohorts, the data reveal patterns that can inform product positioning, pricing strategies, and targeted outreach. Moreover, the direct patient interaction inherent in support programs enables rapid feedback loops, allowing manufacturers to refine therapeutic approaches in near real‑time.

Complementing support programs, patient registries offer a longitudinal view of the therapeutic journey, especially where program data are sparse. In Canada, robust provincial and disease‑specific registries track continuity of care, capture long‑term safety signals, and document outcomes across diverse care settings. Leveraging these registries helps companies build comprehensive evidence packages that satisfy regulators, payers, and clinicians alike. As the industry moves toward outcomes‑based contracts, the ability to demonstrate sustained benefit through registry data will become a decisive competitive advantage, driving both patient access and commercial success.